CHRS Latest News, Press Relases and Analysis

All

Press Releases

15 days ago - By: Coherus Oncology, Inc.

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

15 days ago - By: Coherus Oncology, Inc.

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

15 days ago - By: Zacks Investment Research - Mentions: ARMP

Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates

15 days ago - By: Coherus Oncology, Inc.

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

16 days ago - By: Benzinga - Mentions: STVN PODD AMRK SOLV ...

Earnings Scheduled For November 6, 2025

17 days ago - By: Benzinga

Coherus BioSciences's Earnings Outlook

4 months ago - By: The Motley Fool

Coherus (CHRS) Q2 Revenue Jumps 10%

15 days ago - By: Coherus Oncology, Inc.

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

16 days ago - By: Coherus Oncology, Inc.

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

16 days ago - By: Coherus Oncology, Inc.

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

23 days ago - By: Coherus Oncology, Inc.

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

23 days ago - By: Coherus Oncology, Inc.

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

a month ago - By: Coherus Oncology, Inc.

Coherus Oncology to Participate in Upcoming Investor Conferences

a month ago - By: Coherus Oncology, Inc.

Coherus Oncology to Participate in Upcoming Investor Conferences

2 months ago - By: Coherus Oncology, Inc.

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

2 months ago - By: Coherus Oncology, Inc.

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

3 months ago - By: Coherus Oncology, Inc.

Coherus Oncology to Participate in Upcoming Investor Conferences

4 months ago - By: Zacks Investment Research - Mentions: FBIO

Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates

4 months ago - By: Coherus Oncology, Inc.

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Coherus Oncology, Inc.

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Zacks Investment Research - Mentions: RCUS

Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2

4 months ago - By: Coherus Oncology, Inc.

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

4 months ago - By: Coherus Oncology, Inc.

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

6 months ago - By: Yahoo Finance - Mentions: ENB VCYT IART NEM ...

Enbridge Is One of the Largest Energy Companies by Market Cap. But Is It a Buy?

6 months ago - By: Yahoo Finance - Mentions: VZ ACOG APLS VRTX ...

Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory

6 months ago - By: Yahoo Finance - Mentions: VZ JPM ARGX AXON ...

argenx SE (ARGX): A Bull Case Theory

6 months ago - By: Yahoo Finance - Mentions: VZ ARGX NFE PLUG ...

Coherus BioSciences, Inc. (CHRS): A Bull Case Theory

6 months ago - By: Coherus Oncology, Inc.

Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics

6 months ago - By: Coherus BioSciences, Inc.

Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)

6 months ago - By: Coherus BioSciences, Inc.

Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)

6 months ago - By: Zacks Investment Research - Mentions: BRTX

COHERUS ONCOLOGY INC (CHRS) Stock News

CHRS Latest News, Press Relases and Analysis

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

Earnings Scheduled For November 6, 2025

Coherus BioSciences's Earnings Outlook

Coherus (CHRS) Q2 Revenue Jumps 10%

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

Coherus Oncology to Participate in Upcoming Investor Conferences

Coherus Oncology to Participate in Upcoming Investor Conferences

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Coherus Oncology to Participate in Upcoming Investor Conferences

Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Enbridge Is One of the Largest Energy Companies by Market Cap. But Is It a Buy?

Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory

argenx SE (ARGX): A Bull Case Theory

Coherus BioSciences, Inc. (CHRS): A Bull Case Theory

Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics

Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)

Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)

Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates